Artificial crystalline len with transforming growth factor resistant beta2 antibody membrane on surface and manufacturing method thereof

Abstract

The invention provides an artificial lentis, which contains anti-transforming growth factor beta 2 antibody membrane on the surface and can inhibit intercurrent post-cataract after cataract surgery, and also provides a the production method thereof. The production method includes the steps that: the artificial lentis is charged with positive electricity or negative electricity after the artificial lentis is cleaned, dried, and pretreated on the surface; the artificial lentis is soaked in a polyelectrolyte solution the charge of which is opposite to the surface charge of the artificial lentis for adsorbing, and rinsing the artificial lentis by deionized water, and drying the artificial lentis by nitrogen gas; the artificial lentis is soaked in a phosphate buffering solution of anti-transforming growth factor beta 2 antibody, the pH value of which is 4-10, and the carried charge of which is opposite to that of the polyelectrolyte, for adsorption; finally, the artificial lentis is rinsedby phosphate buffering solution, and the artificial lentis is dried by nitrogen gas; the alternating assembly steps are repeated. The artificial lentis of the invention can inhibit the transformationand differentiation as well as cyst membrane shrinkage of the lentis epithelial cells in a target way, and then interdicts the occurrence of the post-cataract, and has excellent biocompatibility. Theproduction method of the invention is scientific and simple, and can ensure the activity under a dry state and the safety and reliability during medical transplantation of the anti-transforming growth factor beta 2.

Description

technical field [0001] The invention relates to an intraocular lens used for replacing the intraocular lens in cataract surgery, in particular to an intraocular lens with an anti-transforming growth factor β2 antibody film on the surface capable of inhibiting subsequent postoperative cataract and its manufacturing method . Background technique [0002] After cataract is a complication formed after extracapsular cataract extraction due to the incomplete absorption of the residual lens cortex and the remaining part of secondary opacity, so it is also called posterior capsular opacity or secondary cataract; this eye disease will directly affect to restore the patient's vision. At present, with the improvement of extracapsular cataract extraction, the incidence of post-cataract has dropped from 50% in the early stage, but 14.1-18.8% of postoperative patients still need to receive Nd-YAG laser surgery (that is, neodymium-doped yttrium aluminum Posterior capsulotomy with garnet ...

AI Technical Summary

Problems solved by technology

Although they can play a role in inhibiting the proliferation of residual lens epithelial cells in situ by local high-concentration drugs, and have the effect of in vitro tests, they have been found to have the following disadvantages in vivo tests: 1) coated on the surface of the intraocular lens Antiproliferative cytotoxic drugs or drug sustained release carriers, which have potential toxic side effects on corneal endothelial cells, iris, ciliary body epithelial cells, retina and other intraocular tissues; in addition, other delivery methods include intracapsular Drug lavage, intraocular implantation of biodegradable polymer drug slow-release carriers, etc. The disadvantage of the former is that the effective concentration is maintained for a short time and it is easy to affect other tissues in the eye, while the latter is easy to affect intraocular tissues or Interfere with other operations, and once toxic side effects occur, they need to be removed immediately; 2) The stability of the drug coating on the surface of the intraocular lens is relatively poor, so it is not reliable to use; 3) Their manufacturing process is relatively complicated

Images